Research Management Committee

INDEPENDENT. INTERNATIONAL. LEADERS.

 

The Research Management Committee (RMC) is made up of independent members whose primary role is to evaluate research proposals and actively help BioCanRx monitor the progress of its projects. The RMC will build and maintain a robust, competitive research portfolio founded on scientific excellence and network goals. All RMC funding and budget recommendations go to the Board of Directors for approval.

 

In order to avoid potential conflicts of interest, the voting RMC is composed of independent and primarily international experts in biotherapeutics.

 

Membership

 

stephanrussell-1
robertcoffin-2
jhoch
Dr. Stephen Russell
Chair, RMC, Professor, Molecular Medicine
Consultant, Hematology
Mayo Clinic (USA)
Dr. Robert Coffin
CEO & Director, Replimune
Awen Gallimore, PhD
Professor, Immunology, Infection and Immunity, Cardiff University
Dr. Jeffrey Hoch
Professor, Department of Public Health Sciences, UC Davis
cpeetz
smandrekar
grantmcfadden-1
alanmelcher-1
Chris Peetz
Entrepreneur-in-Residence,
Frazier Healthcare/Flashpoint Therapeutics
Dr. Sumithra Mandrekar
Professor of Biostatistics and Oncology at the Mayo Clinic (USA)
Dr. Grant McFadden
Director, Center for Immunotherapy, Vaccines, and Virotherapy Biodesign Institute, Arizona State U, Tempe, AZ (USA)
Dr. Alan Melcher
Professor of Translational Immunotherapy, The Institute of Cancer Research, Chester Beatty Laboratories, London (UK)
iramellman-1
nonetto
clionarooney-1
Dr. Ira Mellman
Vice-President, Cancer Immunology, Genentech (USA)
Dr. Nicole Onetto
Former Deputy Director and Chief Scientific Officer, Ontario Institute for Cancer Research (Canada)
Isabelle Rivière, PhD
Director, Michael G. Harris Cell Therapy and Cell Engineering Facility, Molecular Pharmacology at Memorial Sloan Kettering Cancer Center
Dr. Cliona Rooney
Professor, Baylor College of Medicine (USA)
seet190
len-seymour
stevexanthoudakis-1
Dr. Bruce Seet
Director, Medical Affairs, Sanofi-Pasteur (Canada)
Dr. Len Seymour
Founder and Chief Scientific Officer, Oxford Genetics (UK)
Dr. Steven Xanthoudakis
Chief Business Development Officer, Quebec Consortium for Drug Discovery (CQDM)

 

EX-OFFICIO MEMBERS (NON-VOTING)

 

Dr. John Bell
BioCanRx Scientific Director
Senior Scientist, the Ottawa Hospital Research Institute
Professor, uOttawa

 

Dr. Kelvin Chan
Associate Scientist, Sunnybrook Health Sciences Centre (Canada)

 

Dr. Jason Moffat
BioCanRx Theme Leader
Associate Professor, Canada Research Chair in Functional Genomics of Cancer, University of Toronto

 

Dr. Brad Nelson
BioCanRx Theme Leader
Director and Distinguished Scientist, Deeley Research Centre, BCCA
Professor, Biochemistry and Microbiology, University of Victoria

 

Dr. Claude Perreault
Principal Investigator, IRIC
Professor, Faulty of Medicine, Université de Montréal
Hematologist, Maisonneuve-Rosemont Hospital

 

 

OBSERVERS

 

Dr. Stéphanie Michaud
President and CEO, BioCanRx

 

Dr. Jennifer Quizi
Director, Scientific Affairs, BioCanRx

 

Alex Pigeon
Senior Program Manager, Networks of Centres of Excellence